Colitis and Crohn's Disease Research

We are currently recruiting for ulcerative colitis:

Etrolizumab HICKORY/COTTONWOOD Study: A Phase 3, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors.

This study is currently recruiting patients who are intolerant or refractory to 1-2 of the following TNF-inhibitors w/in the previous 5 yrs: Adalimumab and Golimumab.

Receptos TRUE NORTH Study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis. This study is currently enrolling patients who are intolerant to Ant-TNFs EXCEPT for Tysabri.

We will be recruiting for Crohn's disease in the future:

Mongersen REVOLVE Study: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.

We plan on starting recruitment in the fourth quarter of 2016.

Please contact Jeannie Hom, CRC (415) 514-8947 or for more information.

Related Information

Contact Us

To reach the Colitis and Crohn's Disease Center, call (415) 353-7921.

Our Experts

Uma Mahadevan
Dr. Uma Mahadevan,
Jonathan Terdiman
Dr. Jonathan Terdiman,